Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis | Zendy

William J. Sandborn | Zendy; Brian G. Feagan | Zendy; Geert R. DʼHaens | Zendy; Douglas C. Wolf | Zendy; Igor Jovanović | Zendy; Stephen B. Hanauer | Zendy; Subrata Ghosh | Zendy; AnnKatrin Petersen | Zendy; Steven Y. Hua | Zendy; Ji Hwan Lee | Zendy; Lorna Charles | Zendy; Denesh K. Chitkara | Zendy; Keith Usiskin | Zendy; Jean–Frédéric Colombel | Zendy; Loren Laine | Zendy; Silvio Danese | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

Author(s) -

William J. Sandborn,

Brian G. Feagan,

Geert R. DʼHaens,

Douglas C. Wolf,

Igor Jovanović,

Stephen B. Hanauer,

Subrata Ghosh,

AnnKatrin Petersen,

Steven Y. Hua,

Ji Hwan Lee,

Lorna Charles,

Denesh K. Chitkara,

Keith Usiskin,

Jean–Frédéric Colombel,

Loren Laine,

Silvio Danese

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2033617

Subject(s) - medicine , placebo , ulcerative colitis , cohort , maintenance therapy , population , clinical endpoint , clinical trial , surgery , disease , pathology , chemotherapy , alternative medicine , environmental health

Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore